TuHURA Biosciences
HURA
24 hedge funds and large institutions have $6.31M invested in TuHURA Biosciences in 2021 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 2 reducing their positions, and 4 closing their positions.
250% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 2
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
60% more capital invested
Capital invested by funds: $3.95M → $6.31M (+$2.36M)
14% more funds holding
Funds holding: 21 → 24 (+3)
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$922K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$207K |
| 3 |
State Street
Boston,
Massachusetts
|
+$155K |
| 4 |
BlackRock
New York
|
+$124K |
| 5 |
GSEP
Golden State Equity Partners
South Coast Metro,
California
|
+$118K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$623K |
| 2 |
Renaissance Technologies
New York
|
-$81K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$51.7K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$21K |
| 5 |
SFS
Sowell Financial Services
North Little Rock,
Arkansas
|
-$10K |
HURA Hedge Fund Activity: Q2 2021 in Review
24 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in TuHURA Biosciences (HURA) for Q2 2021, worth a combined $6.31M — up 60% from $3.95M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new HURA positions and 4 closed out — a net gain of 3 holders — while 7 added to existing stakes and 2 trimmed.
The largest buyer was Vanguard Group, adding an estimated $922K. The largest seller was Nantahala Capital Management, cutting an estimated $623K.
- 24 institutional investors held TuHURA Biosciences (HURA) as of Q2 2021, up from 21 in Q1 2021.
- Funds reported $6.31M of TuHURA Biosciences stock for Q2 2021, up 60% quarter-over-quarter.
- 7 funds opened new TuHURA Biosciences positions in Q2 2021 and 4 closed out, a net change of +3 holders.
- The largest TuHURA Biosciences buyer in Q2 2021 was Vanguard Group, an estimated $922K added.
- The largest TuHURA Biosciences seller in Q2 2021 was Nantahala Capital Management, an estimated $623K sold.
Based on aggregated 13F filings for Q2 2021.